Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation

SCHOFIELD, Wis., April 24, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research had issued a research opinion on the company and its flagship product, LipiGesic® M.
 
Report Highlights

- Non-Prescription Product to Treat Migraine Headaches
- Product Shown to Outperform #1 Prescription Competitor
- Holds Patent on Product
- Product Currently Available Walgreen's and CVS/pharmacy stores Nationwide
- Expanding Retail Chain-Store Distribution
- Launching Marketing and Distribution Campaign
- 34 Million Shares Outstanding
- Market Cap just under $1 Million

PuraMed has contracted both bulk manufacturing and packaging firms to assist in the planned national expansion of LipiGesic M, their over-the-counter migraine relief product. The Company commented that they had selected Hillestad Pharmaceuticals as their fully licensed OTC drug manufacturer, with both Unette Corporation and Proteus Packaging to assist in packaging of products for store shelves.
 
This comes on the heels of news that their over-the-counter migraine pain reliever product was currently in Walgreen's and CVS/pharmacy stores nationwide, and PuraMed BioScience plans to expand that retail placement to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.

Current Valuation
Based on current and planned distribution to some of the nation's largest retail drug chains, and having the infrastructure to fulfill orders, PMBS now has all the pieces in place to expand product sales. With just around 34 million common shares outstanding, and a market cap valuation of around $850,000 Ludlow Research feels there could be some good speculative upside potential.

To view the full report, and access risks, disclosures, and potential outlook visit http://www.wallstreetnewscast.com/profile/pmbs.html

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Melissa Diaz,
South Street Media, Inc
Phone: (917) 937-8968
Email: [email protected]

SOURCE PuraMed BioScience, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED